# Identification of the Carcinogenic Process from Lobular Endocervical Glandular Hyperplasia to Gastric-Type Adenocarcinoma of the Uterine Cervix via Whole-Exome Sequencing

**Authors:** Airi Kuruma, Tatsuo Masuda, Kazuaki Sato, Kansuke Kido, Daisuke Motooka, Naoko Komura, Takeshi Yokoi, Kosuke Yoshihara, Yasuto Kinose, Kae Hashimoto, Kenjiro Sawada, Eiichi Morii, Tadashi Kimura, Michiko Kodama

PMC · DOI: 10.3390/cancers18040651 · 2026-02-17

## TL;DR

This study uses whole-exome sequencing to trace the genetic changes from a precancerous cervical condition to a rare, aggressive cervical cancer, revealing possible pathways and key mutations involved.

## Contribution

The study identifies sequential genetic transitions and candidate mutations in the progression from lobular endocervical glandular hyperplasia to gastric-type adenocarcinoma of the uterine cervix.

## Key findings

- Some cases show a sequential transition from lobular endocervical glandular hyperplasia to gastric-type adenocarcinoma.
- Mutations in PTPRF, PTPRT, STK11, and ARID1A are associated with early stages, while SMAD4 and SMAD2 alterations occur in later stages.
- Phylogenetic analysis reveals heterogeneous pathways of tumor development in different cases.

## Abstract

Gastric-type adenocarcinoma of the uterine cervix is a rare but aggressive cancer that is difficult to detect early and often has a poor prognosis. Lobular endocervical glandular hyperplasia is considered a possible precursor lesion, but the genetic relationship between these lesions has not been fully clarified. In this study, we analyzed tissue samples of normal cervical glands, lobular endocervical glandular hyperplasia, and gastric-type adenocarcinoma obtained from the same patients using whole-exome sequencing. By comparing genetic alterations across these lesions, we found that some cases showed evidence supporting a sequential transition from lobular endocervical glandular hyperplasia to gastric-type adenocarcinoma, whereas other cases appeared to develop through alternative pathways. We also identified candidate genetic changes that may occur at early and late stages of tumor development. These findings provide new insights into the heterogeneous carcinogenic processes of this rare cervical cancer and may contribute to improved understanding of its development and inform future research on diagnosis and treatment.

Background: Gastric-type adenocarcinoma (GAS) of the uterine cervix is a rare malignancy with poor clinical outcomes. However, the carcinogenic processes involved remain unclear. Methods: Normal cervical glands, lobular endocervical glandular hyperplasia (LEGH), and GAS from the same patients were collected using laser microdissection for whole-exome sequencing. Single nucleotide variants (SNVs) and copy number alterations (CNAs) were analyzed. Phylogenetic trees were constructed based on the SNV and CNA profiles. Results: Analysis of seven matched samples demonstrated higher frequency of somatic mutations in the exonic regions in GAS than in LEGH. CNAs were prevalent in GAS but rare in LEGH. The phylogenetic analyses revealed various branching patterns. However, in three cases, the data suggested a sequential transition from LEGH to GAS, potentially associated with mutations in receptor-type protein tyrosine phosphatases such as PTPRF and PTPRT. STK11 and ARID1A mutations were present in LEGH, with an increased variant allele frequency observed in GAS. In contrast, SMAD4 and SMAD2 showed frequent loss-of-function–type alterations in GAS, including copy-number loss, but were not detected in LEGH. Conclusions: These findings provide insights into the genomic landscapes of LEGH and GAS and suggest potential molecular markers for this transition, which may inform future diagnostic and therapeutic research.

## Linked entities

- **Genes:** PTPRF (protein tyrosine phosphatase receptor type F) [NCBI Gene 5792], PTPRT (protein tyrosine phosphatase receptor type T) [NCBI Gene 11122], STK11 (serine/threonine kinase 11) [NCBI Gene 6794], ARID1A (AT-rich interaction domain 1A) [NCBI Gene 8289], SMAD4 (SMAD family member 4) [NCBI Gene 4089], SMAD2 (SMAD family member 2) [NCBI Gene 4087]

## Full-text entities

- **Genes:** SMARCA4 (SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4) [NCBI Gene 6597] {aka BAF190, BAF190A, BRG1, CSS4, MRD16, OTSC12}, MUC6 (mucin 6, oligomeric mucus/gel-forming (gene/pseudogene)) [NCBI Gene 4588] {aka MUC-6}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, ERBB3 (erb-b2 receptor tyrosine kinase 3) [NCBI Gene 2065] {aka ErbB-3, FERLK, HER3, LCCS2, MDA-BF-1, VSCN1}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, SMAD2 (SMAD family member 2) [NCBI Gene 4087] {aka CHTD8, JV18, JV18-1, LDS6, MADH2, MADR2}, PTPRF (protein tyrosine phosphatase receptor type F) [NCBI Gene 5792] {aka BNAH2, LAR}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, SLX4 (SLX4 structure-specific endonuclease subunit) [NCBI Gene 84464] {aka BTBD12, FANCP, MUS312}, PAGR1 (PAXIP1 associated glutamate rich protein 1) [NCBI Gene 79447] {aka C16orf53, GAS, PA1}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, PMP22 (peripheral myelin protein 22) [NCBI Gene 5376] {aka CIDP, CMT1A, CMT1E, DSS, GAS-3, GAS3}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, SMAD4 (SMAD family member 4) [NCBI Gene 4089] {aka DPC4, JIP, MADH4, MYHRS}, GAS2 (growth arrest specific 2) [NCBI Gene 2620] {aka DFNB125, GAS-2}, GAS5 (growth arrest specific 5) [NCBI Gene 60674] {aka NCRNA00030, SNHG2}, mucin [NCBI Gene 100508689], ARID1A (AT-rich interaction domain 1A) [NCBI Gene 8289] {aka B120, BAF250, BAF250a, BM029, C1orf4, CSS2}, STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, PTPRS (protein tyrosine phosphatase receptor type S) [NCBI Gene 5802] {aka PTP-sigma, PTPSIGMA, R-PTP-S, R-PTP-sigma}, GAS1 (growth arrest specific 1) [NCBI Gene 2619], GAS6 (growth arrest specific 6) [NCBI Gene 2621] {aka AXLLG, AXSF}, ARID1B (AT-rich interaction domain 1B) [NCBI Gene 57492] {aka 6A3-5, BAF250B, BRIGHT, CSS1, DAN15, ELD/OSA1}, MAP2K4 (mitogen-activated protein kinase kinase 4) [NCBI Gene 6416] {aka JNKK, JNKK1, MAPKK4, MEK4, MKK4, PRKMK4}, PTPRT (protein tyrosine phosphatase receptor type T) [NCBI Gene 11122] {aka R-PTP-T, RPTP-rho, RPTPrho}, GNAS (GNAS complex locus) [NCBI Gene 2778] {aka AHO, AIMAH1, C20orf45, GNAS1, GPSA, GSA}
- **Diseases:** breast and thyroid cancers (MESH:D001943), ovarian and endometrial cancers (MESH:D004714), gastrointestinal cancers (MESH:D005770), Endocervical Glandular Hyperplasia (MESH:D006965), hepatocellular carcinoma (MESH:D006528), metastasis (MESH:D009362), Gastric-type adenocarcinoma of the uterine cervix (MESH:C536823), Carcinogenic (MESH:D011230), endometrial cancer (MESH:D016889), LEGH (MESH:D018275), GAS (MESH:D013274), lesion (MESH:D009059), carcinogenesis (MESH:D063646), GAIS (MESH:D065311), VAF (MESH:D006316), non-small cell lung cancer (MESH:D002289), SCC (MESH:D002294), injury to (MESH:D014947), PDAC (MESH:D021441), pancreatic cancer (MESH:D010190), cervical cancer (MESH:D002583), hereditary cancer (MESH:D009386), Cancer (MESH:D009369), AC (MESH:D000230), benign small intestinal tumors (MESH:D007414)
- **Chemicals:** eosin (MESH:D004801), HE (-), Hematoxylin (MESH:D006416), paraffin (MESH:D010232)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** R361C
- **Cell lines:** LEGH — Homo sapiens (Human), Benign prostatic hyperplasia, Transformed cell line (CVCL_1091), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939958/full.md

---
Source: https://tomesphere.com/paper/PMC12939958